# Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

> **NCT03013517** · PHASE3 · UNKNOWN · sponsor: **DBV Technologies** · enrollment: 300 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** Viaskin Peanut 250µg

## Key facts

- **NCT ID:** NCT03013517
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-23
- **Primary completion:** 2019-11-23
- **Final completion:** 2023-03
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013517, "Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03013517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*